CVRx (NASDAQ:CVRX) Stock Rating Upgraded by William Blair

William Blair upgraded shares of CVRx (NASDAQ:CVRX) from a market perform rating to an outperform rating in a report issued on Tuesday, Marketbeat reports. William Blair also issued estimates for CVRx’s Q4 2024 earnings at ($0.35) EPS, FY2024 earnings at ($2.62) EPS, Q1 2025 earnings at ($0.64) EPS, Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($2.08) EPS, Q1 2026 earnings at ($0.55) EPS, Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.35) EPS and FY2026 earnings at ($1.82) EPS.

CVRX has been the subject of several other research reports. Canaccord Genuity Group increased their target price on CVRx from $17.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Cantor Fitzgerald reiterated an “overweight” rating and set a $14.00 target price on shares of CVRx in a research report on Wednesday, October 23rd. Craig Hallum boosted their target price on shares of CVRx from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Monday, November 4th. Piper Sandler reiterated an “overweight” rating and set a $16.00 target price (up previously from $13.00) on shares of CVRx in a research report on Wednesday, October 30th. Finally, Lake Street Capital upped their price objective on shares of CVRx from $12.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, CVRx presently has an average rating of “Moderate Buy” and a consensus target price of $16.67.

CVRx Stock Performance

Shares of CVRX opened at $17.30 on Tuesday. The company’s 50 day moving average price is $14.04 and its 200 day moving average price is $11.05. The company has a debt-to-equity ratio of 0.76, a quick ratio of 10.23 and a current ratio of 11.32. CVRx has a 52 week low of $6.40 and a 52 week high of $29.23. The company has a market capitalization of $419.70 million, a PE ratio of -6.41 and a beta of 1.26.

CVRx (NASDAQ:CVRX) last posted its earnings results on Tuesday, October 29th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.12). CVRx had a negative return on equity of 89.06% and a negative net margin of 123.75%. The business had revenue of $13.37 million during the quarter, compared to the consensus estimate of $13.28 million. During the same period in the prior year, the firm earned ($0.43) earnings per share. Research analysts expect that CVRx will post -2.62 EPS for the current fiscal year.

Institutional Investors Weigh In On CVRx

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. PDT Partners LLC acquired a new position in shares of CVRx during the 3rd quarter worth approximately $543,000. International Assets Investment Management LLC bought a new position in shares of CVRx during the third quarter worth approximately $338,000. Jane Street Group LLC lifted its position in shares of CVRx by 36.1% during the 3rd quarter. Jane Street Group LLC now owns 19,038 shares of the company’s stock valued at $168,000 after acquiring an additional 5,053 shares during the period. Geode Capital Management LLC increased its holdings in CVRx by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 295,124 shares of the company’s stock valued at $2,600,000 after buying an additional 6,443 shares during the period. Finally, State Street Corp lifted its stake in CVRx by 11.4% during the third quarter. State Street Corp now owns 264,733 shares of the company’s stock worth $2,332,000 after purchasing an additional 27,071 shares during the last quarter. 75.27% of the stock is currently owned by institutional investors and hedge funds.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.